Master supervisor of Fudan University. Headof Laboratory of Reproductive Pharmacology, Shanghai Institute of Planned Parenthood Research (SIPPR). PI of Key Laboratory of Contraceptive Drugs and Devices, NHC. PI of Institute of Reproductive and Development of Fudan University. Executive direct of Reproductive Professional Committee of Chinese Pharmacological Society& Shanghai Pharmacological Society. Fellow of Traditional Chinese Medicine Professional Committee of Chinese Pharmacological Society.
       Dr. Yan Zhu received her B.Sc. and M.Sc. degrees from Shenyang Pharmaceutical University, China, and a Ph.D. from Fudan University, China, and accomplished visiting scholar exchange program at the University of British Columbia, Canada, sponsored by China Scholarships Council. Since 1999, Dr. Zhu has been working inSIPPR, one of collaborating center for research in reproduction by the World Health Organization (WHO).
    She devotes to pharmacological study of drugs used in the reproductive system and is good at the evaluationof preclinical pharmacodynamics and toxicity and early drug discoveryin area of birth control and gynecological diseases. Her team establishedvariously experimental models of cells and animals, including antifertility, epididymis infertility, dysmenorrhea, polycystic ovary syndrome, endometriosis, uterine fibroids, and tumors of endometria and ovaries and is experienced in the drug development of birth control, fertility protection and reproductive tumor treatment.
       Dr. ZHU published more than 90 full-length papers (including more than 20 SCI papers) and obtained 6 authorized patent and compiledchapters related to reproductive disease for the book of Pharmacological Experimental Methodology (4th Edition), Pharmacological Research Methodology and Pharmacological Advance Report (2010-2011). Moreover, Dr. ZHU undertook and participated in more than twenty projectsin theNational Key R & D Program, including "Eleventh Five-Year""Twelfth Five-Year"and"Thirteenth Five-Year", National Natural Science Foundation of China, Shanghai Natural Science Foundation.Based on extensive experience, Her teamoffer pharmaceutical companies and institutions withprofessionalservices in PK, PD and bioequivalence evaluation, and these projects were approved by the State Drug Administration and received Drug Clinical Trial Approval or Drugs Registration Approval, including levonorgestrel and ethinylestradiol contraceptive patch, gestodene patch,Jiaweimojie tablets, compound levonorgestrel tablets, etc.Two projects have won the prizes of Excellent Scientific and Technological Achievements from the National Population and Family Planning in the "Eleventh Five-Year Plan".
Research Area
(1). R & D of birth control drugs: Extremely good at pharmacodynamics and toxicologicalresearch of birth control drugs with special rout of administration, such as vagina, uterine cavity and transdermal, etc;
(2). Pharmacodynamic evaluation and mechanism of action of medication for gynecological diseases and tumor: Utilizing the models of cells and animals to evaluate pharmacodynamicsof traditional medicine and chemical compoundsand investigatemechanism of action of medication and perform early drug development in reproductive system. 
(3) Dr. ZHU’s team established a unique approach for PKassayof ultra-low-dose estrogen, progesterone and other steroidal contraceptive using HPLC-MS and radioimmunoassay and able to provide services for the assay of sex hormones and analogues.
Major papers in recent years:
1. Zhu Y*, Klausen C, Zhou J, Guo X, Zhang Y, Zhu H, Li Z, Cheng JC, Xie S, Yang W, Li Y, Leung PCK*. Novel dihydroartemisinin dimer containing nitrogen atoms inhibits growth of endometrial cancer cells and may correlate with increasing intracellular peroxynitrite. Sci Rep. 2019; 9(1):15528. doi: 10.1038/s41598-019-52108-6.(IF=4.0)
2. Cao, C.; Zhou, J.; Xie, S.; Guo, X.; Li, G.; Gong, Y.; Yang, W.; Li, Z.; Zhong, R.; Shao, H.;Zhu, Y*. Metformin Enhances Nomegestrol Acetate Suppressing Growth of Endometrial Cancer Cells and May Correlate to Downregulating mTOR Activity In Vitro and In Vivo. Int. J. Mol. Sci. 2019, 20(13), 3308; https://doi.org/10.3390/ijms20133308. (IF=4.18)
3. Zhong R, Li G, Yang W, Guo X, Li Z, Zhou J, Ma A, Zhu Y*. Hormone-like activities of Kuntai capsule in the uteri of ovariectomized rats and immature rabbits.Journal of Traditional Chinese Medicine.2018, 38(6): 853-861. doi.org/10.1016/S0254-6272(18)30984-1. (IF=0.857)
4. Cao Y, Ye Q, Zhuang M, Xie S, Zhong R, Cui J, Zhou J, Zhu Y*, Zhang T*, Cao L.Ginsenoside Rg3 inhibits angiogenesis in a rat model of endometriosis through the VEGFR-2-mediated PI3K/Akt/mTOR signaling pathway.PLoS One. 2017;12(11):e0186520. doi: 10.1371/journal.pone.0186520. eCollection 2017.(IF=2.8)
5. Ma AY, Xie SW, Zhou JY, ZhuY*.NomegestrolAcetate Suppresses Human Endometrial Cancer RL95-2 Cells Proliferation In Vitro and In Vivo Possibly Related to Upregulating Expression of SUFU and Wnt7a.Int J Mol Sci. 20172;18(7). pii: E1337. doi: 10.3390/ijms18071337.(IF=3.2)
6. ShuwuXie, Guoting Li, Lijuan Qu, RuihuaZhong, Ping Chen, Zhigang Lu, Jieyun Zhou, XiangjieGuo, Zhao Li, Aying Ma, Yueying Qian*, and Yan Zhu*. Podophyllotoxin Extracted from Juniperussabina Fruit Inhibits Rat Sperm Maturation and Fertility by Promoting Epididymal Epithelial Cell Apoptosis. Evidence-Based Complementary and Alternative Medicine. 2017, 2017: 6958982, https://doi.org/10.1155/2017/6958982.(IF=1.74)
7. Xie SW, Li GT, Qu LJ*, Cao Y, Wang Q, Zhou JY, Zhong RH, Guo XJ, Zhu Y*. Identification of New Epididymal Luminal Fluid Proteins Involved in Sperm Maturation in Infertile Rats Treated by Dutasteride Using iTRAQ. Molecules. 2016;21(5). pii: E602. doi: 10.3390/molecules21050602. (IF=2.47)
8. Zhong R, Ma A, Zhu J, Li G, Xie S, Li Z, Gui Y, Zhu Y*.Kuntai Capsule Inhibited Endometriosisvia Inducing Apoptosis in a Rat Model. Evid Based Complement Alternat Med. 2016; 2016:5649169. doi: 10.1155/2016/5649169. (IF=1.93)
9. Zhu Y*, Xu JJ, Li Z, Xie SW , Zhou JY, Guo XJ, Zhou XY, Li GT, Zhong RH, Ma AY. Ginsenoside Rh2 suppresses growth of uterine leiomyoma in vitro and in vivo and may regulate ERα/c-Src/p38 MAPK activity. J Funct Foods. 2015; 18( 73-82). DOI: 10.1016/j.jff.2015.06.057. (IF=3.55)
10. Cao Y, Zhuang MF, Yang Y, Xie SW, Cui JG, Cao L, Zhang TT*, Zhu Y*. Preliminary Study of Quercetin Affecting the Hypothalamic-Pituitary-Gonadal Axis on Rat Endometriosis Model. Evid Based Complement Alternat Med.  2014;2014:781684. doi: 10.1155/2014/781684.(IF=2.175)
11. Zhang JF, Zhu Y*, Zhou XY, Hao SF, Xie SW, Zhou JY, Guo XJ, Li Z, Huang YS; Chen QH.  Evaluation of biodegradable microspheres containing nomegestrol acetate in a rat model of endometriosis. Eur J Pharm Sci. 2014,65(18)15–20. DOI: 10.1016/j.ejps.2014.08.011(IF=3.005).
12. He-Lin Lu, Zong-Wen Wu, Shu-Yong Song, Xiao-Dan Liao, Yan Zhu*, Yun-Sheng Huang*. An Improved Synthesis of Nomegestrol Acetate. Org. Process Res. Dev. 2014, 18, 431−436. dx.doi.org/10.1021/op4003533.（IF=2.55）
13. CAO Can，XIE Shu-wu，ZHU Yan*. Progress in researches for normegestrol acetate: a novel progestin.Chinese Journal of NewDrugs.2019,28 (10): 1197-1202.
14. Cao Can, XieShuwu, Zhu Yan*.Effects of Hedgehog signaling pathway in female reproductive system cancer.Chin J ReprodContracep,2018,38(7): 610-13.
15. LI Zhao, GUO Xiang-jie, XIE Shu-wu, ZHOU Jie-yun, ZHU Yan*.Simultaneous determination of levonorgestrel and ethinylestradiolin New Zealand rabbit plasma by liquid chromatography-tandemmass spectrometry and their pharmacokinetics.Chin J PharmacolToxicol,2017, 31 (8): 823-831.
16. LI GUO-ting, ZHONG Rui-hua, ZHOU Jie-yun, XIE Shu-wu, CHEN Ping, QIAN Yue-ying, ZHU Yan*. Study on podophyllotoxin induced rat epididymalepithethial cell apoptosis and its mechanism in vitro. Chinese Pharmacological Bulletin. 2017; 33 (10): 1357~63.
17. GUO Xiang-jie，LI Zhao，XIE Shu-wu，ZHOU Jie-yun，LI Guo-ting，ZHONG Rui-hua，ZHU Yan*. Pharmacokinetics study of gestrinone capsules in Bama min-pigs.Chin J Pharm Anal. 2017,37(7):1182-1188.
18. MA A-ying，XIE Shu-wu，ZHU Yan. Progress in drug treatment of endometrial hyperplasia.Chinese Journal of NewDrugs.2016 ,25(23): 2683-2687.
19. ZHU Yan.Review and progress of reproductive pharmacology.Chin J PharmacolToxicol,2015;29(5):763-764.
20. ZHOU Jie-yun ZHOU Xian-ying LI Zhao LI Guo-ting ZHONG Rui-hua XIE Shu-wu ZHU Yan*. Experimental Study of“Qumo Granule”on AbnormalUterine Haemorrhage Induced by Mifepristone.J Shanghai University of Traditional Chinese Medicine..2015:25（9）: 69-73.
21. Rui-hua ZHONG, Xian-ying ZHOU, Shu-wu XIE, Guo-ting LI, A-yingMA,Zhao LI, You-lunGUI, Jian-ping ZHU*, Yan ZHU*. Effect of Kuntai capsule on ectopic endometrium andthe pregnancy outcome in a rat of endometriosisReproduction & Contraception.2015,35（85）:17-524.
22. BI Ji -hong， GUO Xiang- jie， LI Zhao， XU Hong- rong， GUI You- lun， ZHU Jian- ping，LI Xue-ning*， ZHU Yan*. Bioequivalence of desogestrel/ethinylestradiol tablets in healthy Chinese Hannationality volunteers. Chin J New Drugs Clin Rem.2015，34（1）：51-57.
23. XIE Shu-wu, Qu Li-juan, Zhou Xian-ying, ZHOU Jie-yun, Li Guo-ting, Bi Ji-hong, Guo Xiang-jie, LI Zhao, CAO Lin, ZHU Yan*. Inhitibory effect of dutasteride on the expression of epididymalClaudin 1 and β-catenin in male rats.National Journal of Andrology.2015，21（1）：17-22.
24. ZHOU Jie-yun，ZHU Yan*. Progress in Antitumor Effects of Artemisinin and Its Derivatives.Nat Prod Res Dev. 2014，26: 975-981.
25. ZHOU Jie-yun，XIE Shu-wu，ZHANG Yu，LI Guo-ting，GUI You-lun，LI Ying，ZHU Yan*. Anti-tumor activity of SM1052，a novel artemisinin derivative，in the human endometrial carcinoma RL95-2 cells. Journal of NewDrugs.2014, 23( 12):1431-1437.
26. Li Guo-ting,XIE Shu-wu,ZHU Yan*. Advance in development of male contraceptives. Journal of NewDrugs.2014, 23(1): 55-61.
27. ZHU Yan.Advanced trendsin contraceptives.Reproduction & Contraception..2012, 32(4):284-287.
28. Xiang-jie GUO, Zhao LI, You-lun GUI, Zhong-yiZHU,Xian-ping ZHAO, Xue-ning LI, Lin CAO, Yan ZHU*. Study on Pharmacokinetic and Relative Bioavailability of Rapid OralDisintegrating Tablet of LevonorgestrelReproduction & Contraception. .2012, 32(2):92-97.